Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China
· Delayed Price · Currency is CNY 23.00
-0.20 (-0.86%)
Apr 29, 2026, 3:00 PM CST
Aurisco Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 393.72 | 449.21 | 354.79 | 289.42 | 210.96 | 168.71 | Upgrade
|
| Depreciation & Amortization | 125.98 | 125.98 | 88.3 | 79.11 | 69.24 | 54.77 | Upgrade
|
| Other Amortization | 2.33 | 2.33 | 1.9 | 2.54 | 1.55 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.55 | 0.55 | 0.41 | 1.53 | 1.5 | 0.4 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.23 | 0.23 | 0.17 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -10.99 | -10.99 | -5.62 | -31.72 | 1.19 | -0.68 | Upgrade
|
| Provision & Write-off of Bad Debts | 7.66 | 7.66 | 3.55 | 4.18 | 4.19 | -0.09 | Upgrade
|
| Other Operating Activities | 165.9 | 47.88 | 20.4 | 6 | 3.89 | 2.33 | Upgrade
|
| Change in Accounts Receivable | -125.57 | -125.57 | -107.13 | -98.18 | -84.83 | 11.29 | Upgrade
|
| Change in Inventory | -121.19 | -121.19 | -201.43 | -72.52 | -125.97 | -89.01 | Upgrade
|
| Change in Accounts Payable | 42.67 | 42.67 | 161.15 | 174.55 | 70.56 | 55.41 | Upgrade
|
| Change in Other Net Operating Assets | 5.23 | 5.23 | 17.59 | 34.28 | 17.98 | 1 | Upgrade
|
| Operating Cash Flow | 484.02 | 421.5 | 332.41 | 385.61 | 166.41 | 201.57 | Upgrade
|
| Operating Cash Flow Growth | 80.15% | 26.80% | -13.80% | 131.72% | -17.44% | -6.02% | Upgrade
|
| Capital Expenditures | -351.74 | -350.07 | -540.28 | -305.48 | -216.23 | -250.61 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.98 | 1.04 | 1.28 | 0.52 | 0.63 | 0.6 | Upgrade
|
| Divestitures | - | - | - | 61.09 | - | - | Upgrade
|
| Investment in Securities | -5.57 | 106.74 | -191.34 | -121.44 | -41.44 | -15 | Upgrade
|
| Other Investing Activities | 1.94 | 0.11 | 3.56 | 0.03 | 0.25 | 2.68 | Upgrade
|
| Investing Cash Flow | -354.38 | -242.19 | -726.77 | -365.27 | -256.79 | -262.34 | Upgrade
|
| Long-Term Debt Issued | - | 66 | 986.04 | 135.79 | 37.12 | - | Upgrade
|
| Total Debt Issued | 59.1 | 66 | 986.04 | 135.79 | 37.12 | - | Upgrade
|
| Long-Term Debt Repaid | - | -68.17 | -153.64 | -71.87 | -5.94 | -4.37 | Upgrade
|
| Total Debt Repaid | -82.45 | -68.17 | -153.64 | -71.87 | -5.94 | -4.37 | Upgrade
|
| Net Debt Issued (Repaid) | -23.34 | -2.17 | 832.4 | 63.92 | 31.18 | -4.37 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 57.15 | - | Upgrade
|
| Repurchase of Common Stock | -55.13 | -55.13 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -124.03 | -124.12 | -94.82 | -67 | -52.34 | -48.12 | Upgrade
|
| Other Financing Activities | 45.31 | - | -3.22 | 52.1 | -50.9 | - | Upgrade
|
| Financing Cash Flow | -157.19 | -181.42 | 734.37 | 49.02 | -14.91 | -52.49 | Upgrade
|
| Foreign Exchange Rate Adjustments | -19.75 | -3.55 | 14.02 | 6.11 | 3.5 | -3.82 | Upgrade
|
| Net Cash Flow | -47.3 | -5.66 | 354.02 | 75.47 | -101.79 | -117.08 | Upgrade
|
| Free Cash Flow | 132.29 | 71.42 | -207.87 | 80.13 | -49.82 | -49.04 | Upgrade
|
| Free Cash Flow Margin | 7.85% | 4.21% | -14.09% | 6.35% | -4.94% | -6.11% | Upgrade
|
| Free Cash Flow Per Share | 0.32 | 0.17 | -0.52 | 0.20 | -0.12 | -0.12 | Upgrade
|
| Cash Income Tax Paid | 41.16 | 17.92 | -12.74 | -18.15 | -35.73 | -27.6 | Upgrade
|
| Levered Free Cash Flow | 31.68 | -39.07 | -309.03 | 36.02 | -102.36 | -116.14 | Upgrade
|
| Unlevered Free Cash Flow | 53.38 | -17.38 | -299.17 | 37.73 | -101.73 | -115.74 | Upgrade
|
| Change in Working Capital | -201.33 | -201.33 | -131.5 | 34.55 | -126.11 | -23.88 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.